AAIC 2021: Six Ways the Approval of Aducanumab Will Change Alzheimer’s Clinical Trials
XTalks
AUGUST 23, 2021
For example, after Bayer’s Betaseron (interferon beta-1b) was approved as the first treatment for relapsing-remitting multiple sclerosis (MS) in 1993, subsequent trials eventually replaced their placebo control arms with an active comparator arm, explained Kathy Costello, vice president of programs at Can Do Multiple Sclerosis.
52 
Let's personalize your content